Cellular membrane affinity chromatography kit for drug discovery
Cellular membrane affinity chromatography kit for drug discovery
批准号:
10506915
负责人:
Lukasz Michal Ciesla
金额:
$2.68万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-07-01 至 2023-12-31
关键词:
AddressAdoptionAffinity ChromatographyAlabamaAntibodiesArtificial MembranesBindingBiological AssayBuffersCell membraneCell physiologyCellsCellular AssayCellular MembraneCharacteristicsChemicalsChemistryColumn ChromatographyComplexComplex MixturesConsumptionDataData AnalysesDevelopmentDiabetes MellitusDialysis procedureDrug TargetingEnzymesFishesG-Protein-Coupled ReceptorsGoalsImmobilizationIndividualIntegral Membrane ProteinIon ChannelLaboratoriesLeadLibrariesLigandsMalignant NeoplasmsMembrane ProteinsMethodologyMethodsModernizationNational Center for Complementary and Integrative HealthNatural Product DrugNatural ProductsNatureNeurodegenerative DisordersNeurotrophic Tyrosine Kinase Receptor Type 2Particle SizePerformancePharmaceutical PreparationsPharmacodynamicsPharmacologic SubstancePharmacologyPhasePhytochemicalPlant ExtractsPreparationProceduresProcessPropertyProtein Tyrosine KinaseProteinsProtocols documentationResearchResearch PersonnelResourcesSamplingSmokeSolidSourceSpeedSurfaceTechniquesTechnologyTemperatureTestingTimeUniversitiesValidationbasechronic paincommercializationcostdesigndrug candidatedrug discoveryhigh throughput screeningimprovedinnovationinterestnew technologynovelnovel strategiesnovel therapeuticsparticlepressurepreventprogramsreceptorscaffoldscreeningtool
中文摘要
项目摘要
天然产品是一个丰富的来源,植物活性化合物。然而,由于技术限制,
目前使用的高通量筛选技术与复杂的天然样品不相容。一
从天然产物中鉴定新药先导物的最大挑战之一是
提取物,这需要大量的时间和精力来发现具有生物活性的次级代谢产物。
传统的筛选方法通常需要通过化学方法从混合物中分离出单个化合物。
分离,然后是去复制和测定分析,这是耗时的、劳动密集的和昂贵的。
高通量筛选技术主要集中于单个化合物的合成文库,而不是
与混合物相容。相比之下,蛋白质靶点固定技术可以直接钓出结合
这些化合物消除了分离单个化合物的需要。不幸的是,大多数蛋白质
固定化方法存在化合物与载体表面的显著非特异性结合的问题,
这使得它们不适于筛选复杂的混合物。此外,大多数固定化的目标
固体表面上的蛋白质目前限于胞质蛋白质如酶或抗体。这是一
这是一个巨大的限制,因为超过50%的现代药物使用膜蛋白作为主要靶点。
细胞膜亲和层析(CMAC)是一种允许鉴定
化合物,存在于复杂的基质中,并与固定的跨膜
蛋白CMAC柱已被证明是有用的筛选植物提取物和烟雾冷凝物的新的
靶向不同类型跨膜蛋白的配体。然而,阻止这种情况发生的一个挑战是,
CMAC应用较广的一个缺点是CMAC色谱柱的制备方法相对复杂,且缺乏简便易行的方法。
使用捕获和释放色谱试剂盒。我们提出了一种新颖的和专利的CMAC套件的发展
优化了CMAC柱的制备方案。使用这种新方法均质化细胞
将含有靶蛋白的膜片段固定在单独生产的IAM.PC.DD2柱上
关于Regis Technologies使用预填充柱的固定步骤消除了对溶解的需要
和当前方案中使用的透析步骤。新开发的CMAC套件将加快识别
针对跨膜蛋白的植物化学物质。这种新的测定法将理想地适合于构建以下文库:
这些活性天然化合物可以进一步使用现代筛选平台进行测试。
CMAC也是一种可以取代基于功能细胞的测定来确定某些药效学的工具。
候选药物的性质,例如:Kd(结合50%受体的药物浓度)。的
CMAC试剂盒可以很容易地应用于药物发现实验室,以识别可以进一步开发的新药模板。
用于治疗某些形式的癌症,神经退行性疾病,慢性疼痛,糖尿病和许多其他疾病
疾病。
英文摘要
Project Summary
Natural products are a rich source of pharmacologically active compounds. However, due to technical constrains
the currently used high-throughput screening techniques are not compatible with complex natural samples. One
of the greatest challenges in the identification of new drug leads from natural products is the complexity of the
extracts, that requires enormous amount of time and effort to discover biologically active secondary metabolites.
Traditional screening methods often require isolation of individual compounds from mixtures through chemical
separation, followed by derepliction and assay analysis, which are time consuming, labor intensive, and costly.
High throughput screening techniques mainly focus on synthetic libraries of individual compounds and are not
compatible with mixtures. In contrast, protein target immobilization techniques can directly fish out binding
compounds eliminating the need to isolate individual compounds. Unfortunately, most of the protein
immobilization methodologies suffer from significant non-specific binding of compounds to support surfaces,
which makes them not suitable for screening complex mixtures. In addition, the majority of the immobilized target
proteins on solid surfaces are currently limited to cytosolic proteins, such as enzymes or antibodies. This is a
great limitation, because over 50% of all modern pharmaceuticals use membrane proteins as prime targets.
Cellular membrane affinity chromatography (CMAC) is an approach that allows for the identification of
compounds, present in complex matrices and specifically interacting with the immobilized transmembrane
protein. CMAC columns have proven to be useful in screening plant extracts and smoke condensates for new
ligands targeting different classes of transmembrane proteins. However, one of the challenges that prevents
CMAC from wider use is the relatively complex preparation protocol of CMAC columns and the lack of easy-to-
use catch and release chromatographic kits. We propose the development of a novel and patentable CMAC kit
with an optimized preparation protocol of CMAC columns. Using this novel approach homogenized cell
membrane fragments with the targeted proteins will be immobilized on IAM.PC.DD2 columns, produced solely
by Regis Technologies. The immobilization step using pre-packed columns eliminates the need for solubilization
and dialysis steps used in the current protocol. The newly developed CMAC kit will speed up the identification of
phytochemicals targeting transmembrane proteins. This novel assay will be ideally suited to build libraries of
pharmacologically active natural compounds that further might be tested using modern screening platforms.
CMAC is also a tool that can replace functional cell-based assays in determining certain pharmacodynamic
properties of drug candidates, for example: Kd (the concentration of drug that binds 50% of the receptors). The
CMAC kit can easily be applied in drug discovery laboratories to identify novel drug templates that can be further
used to treat certain forms of cancer, neurodegenerative diseases, chronic pain, diabetes and many other
illnesses.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
细胞膜亲和层析柱鉴定与固定化原肌球蛋白激酶受体 B 相互作用的特殊植物代谢物
DOI:
10.3791/63118
发表时间:
2022
期刊:
Journal of Visualized Experiments
影响因子:
--
作者:
[Arituluk, Zekiye Ceren, Adhikari, Bishnu, Maitra, Urmila, Goodman, Caroline, Ciesla, Lukasz M.]
通讯作者:
Ciesla, Lukasz M.
Centella asiatica effects on neuroinflammatory responses in Drosophila models of acute inflammation and aging
-
批准号:10415346
-
项目类别:
-
资助金额:$7.45万
-
财政年份:2022
-
负责人:Lukasz Michal Ciesla
-
依托单位:
Cellular membrane affinity chromatography kit for drug discovery
-
批准号:10325006
-
项目类别:
-
资助金额:$22.39万
-
财政年份:2021
-
负责人:Lukasz Michal Ciesla
-
依托单位:
海外基金